Genertec Universal Medical Group Co Ltd
HKEX:2666

Watchlist Manager
Genertec Universal Medical Group Co Ltd Logo
Genertec Universal Medical Group Co Ltd
HKEX:2666
Watchlist
Price: 5.02 HKD -0.79%
Updated: May 17, 2024
Financials Section:
Income Statement Balance Sheet Cash Flow Statement

Balance Sheet

80.3B
-5%
Assets
Growth Rates:
1 Year
+4%
3 Years
+31%
5 Years
+70%
7 Years
+177%
10 Years
-
63B
-7%
Liabilities
Growth Rates:
1 Year
+3%
3 Years
+28%
5 Years
+69%
7 Years
+181%
10 Years
-
17.4B
+3%
Equity
Growth Rates:
1 Year
+11%
3 Years
+40%
5 Years
+73%
7 Years
+164%
10 Years
-

Balance Sheet Decomposition
Genertec Universal Medical Group Co Ltd

80.3B
Assets
63B
Liabilities
80.3B
Assets
63B
Liabilities
Current Assets 30.7B
Cash & Short-Term Investments 2.9B
Receivables 25.7B
Other Current Assets 2.1B
Non-Current Assets 49.6B
Long-Term Investments 777.7m
PP&E 5.6B
Intangibles 447.8m
Other Non-Current Assets 42.9B
Current Liabilities 30.1B
Accounts Payable 3B
Short-Term Debt 6.6B
Other Current Liabilities 20.5B
Non-Current Liabilities 32.9B
Long-Term Debt 25.1B
Other Non-Current Liabilities 7.8B

Balance Sheet
Genertec Universal Medical Group Co Ltd

Rotate your device to view
Balance Sheet
Currency: CNY
Dec-2014 Dec-2015 Dec-2016 Dec-2017 Dec-2018 Dec-2019 Dec-2020 Dec-2021 Dec-2022 Dec-2023
Assets
Cash & Cash Equivalents
454
1 866
1 272
1 750
2 173
3 386
2 037
2 342
2 679
2 849
Cash Equivalents
454
1 866
1 272
1 750
2 173
3 386
2 037
2 342
2 679
2 849
Short-Term Investments
0
0
0
0
0
0
0
0
150
57
Total Receivables
4 203
5 954
7 031
9 208
11 880
16 422
18 863
21 049
23 997
26 245
Accounts Receivables
4 168
5 919
7 006
9 185
11 826
16 123
0
0
25
26
Other Receivables
35
35
25
23
54
299
0
0
24 022
26 271
Inventory
3
3
2
21
41
157
198
272
388
431
Other Current Assets
101
141
671
949
566
750
735
1 324
921
1 114
Total Current Assets
4 760
7 963
8 976
11 927
14 661
20 714
21 833
25 042
28 161
30 695
PP&E Net
90
90
99
87
271
2 812
3 110
3 334
4 975
5 553
PP&E Gross
90
90
99
87
271
2 812
3 110
3 334
4 975
5 553
Accumulated Depreciation
51
66
88
114
77
125
347
597
995
1 419
Intangible Assets
0
0
0
0
0
0
59
46
79
161
Goodwill
0
0
0
9
9
70
70
102
102
287
Note Receivable
11 471
15 409
19 755
25 385
31 844
33 409
35 533
39 519
41 393
41 542
Long-Term Investments
21
65
65
44
0
449
460
847
761
778
Other Long-Term Assets
43
132
70
280
472
398
447
1 076
1 509
1 329
Other Assets
0
0
0
9
9
70
70
102
102
287
Total Assets
16 385
N/A
23 658
+44%
28 965
+22%
37 733
+30%
47 257
+25%
57 853
+22%
61 511
+6%
69 966
+14%
76 980
+10%
80 345
+4%
Liabilities
Accounts Payable
848
95
194
265
482
1 289
868
1 140
2 266
2 872
Accrued Liabilities
121
220
224
296
487
615
557
720
759
910
Short-Term Debt
0
0
0
0
2 147
2 578
2 317
0
2 519
6 601
Current Portion of Long-Term Debt
4 181
7 635
6 285
10 964
10 200
12 409
17 533
14 746
18 284
15 937
Other Current Liabilities
262
202
471
637
510
1 867
2 044
2 905
2 635
3 753
Total Current Liabilities
5 412
8 151
7 175
12 161
13 826
18 758
23 320
18 791
26 462
30 073
Long-Term Debt
8 472
9 458
14 967
17 800
22 728
25 017
22 398
29 427
29 457
28 606
Minority Interest
0
0
0
0
209
2 306
2 542
2 863
4 080
3 018
Other Liabilities
73
168
249
303
445
630
828
4 120
1 340
1 297
Total Liabilities
13 958
N/A
17 777
+27%
22 390
+26%
30 264
+35%
37 209
+23%
46 711
+26%
49 088
+5%
55 201
+12%
61 340
+11%
62 995
+3%
Equity
Common Stock
1 580
4 328
4 328
4 328
4 328
4 328
4 328
5 297
5 297
5 297
Retained Earnings
846
1 524
2 217
3 112
4 111
5 193
6 394
7 730
8 608
10 375
Other Equity
1
29
29
29
1 609
1 621
1 701
1 737
1 736
1 678
Total Equity
2 427
N/A
5 881
+142%
6 574
+12%
7 469
+14%
10 048
+35%
11 142
+11%
12 423
+11%
14 765
+19%
15 641
+6%
17 350
+11%
Total Liabilities & Equity
16 385
N/A
23 658
+44%
28 965
+22%
37 733
+30%
47 257
+25%
57 853
+22%
61 511
+6%
69 966
+14%
76 980
+10%
80 345
+4%
Shares Outstanding
Common Shares Outstanding
254
1 716
1 716
1 716
1 716
1 716
1 716
1 892
1 892
1 892

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 137,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.